Research programme: monoclonal antibodies - PharmAbcine

Drug Profile

Research programme: monoclonal antibodies - PharmAbcine

Alternative Names: anti-KDR mAb; DIG KT; PIG KM; SSS-25; TRPH 011; VEGFR-2/TIE-2 - PharmAbcine/Triphase Accelerator Corporation

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator PharmAbcine
  • Developer PharmAbcine; Triphase Accelerator Corporation
  • Class Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Proto oncogene protein c met inhibitors; TIE 2 receptor antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Glioblastoma; Pancreatic cancer
  • No development reported Cancer; Inflammation

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in South Korea (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in South Korea (Parenteral)
  • 16 Jan 2015 TRPH 011 licensed to 3SBIO in Greater China (including mainland China, Taiwan, Hong Kong and Macau) and South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top